|
|
Article: NIH panel assesses treatments for insomnia: members conclude that more studies are needed to assess new drugs and alternative therapies.(Neuropsychiatric Medicine)
- Article from:
- Clinical Psychiatry News
- Article date:
- September 1, 2005
- Author:
-
|
Copyright informationCOPYRIGHT 2005 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
New benzodiazepine receptor agonists for chronic insomnia--zaleplon, zolpidem, and eszopiclone--have shown fewer adverse effects compared with other medications, but additional studies are needed to assess these drugs' long-term effectiveness, concluded members of an independent panel convened by the National Institutes of Health in Bethesda, Md.
Only eszopiclone (Lunesta) has been approved for the long-term treatment of insomnia; the other drugs are approved for up to 35 days of use.
Five benzodiazepines--estazolam, flurazepam, quazepam, temazepam, and triazolam--also are approved by the Food and Drug Administration to treat insomnia, but adverse events including ...